We are a clinical-stage biotechnology company discovering and developing novel antiviral therapeutics that target the replication process of coronaviruses (including SARS-CoV-2),  influenza viruses, noroviruses and hepatitis C viruses.  We employ a unique structure-based drug discovery technology platform and Nobel Prize-winning expertise to create first- and best-in-class antiviral drugs.

We are leveraging our core competencies and decade of experience in antiviral therapeutics to combat the global COVID-19 health crisis. Given the growing global need for an effective, safe antiviral treatment, we are advancing multiple antiviral therapeutic candidates targeting SARS-CoV-2 as quickly and efficiently as possible, while also advancing the discovery and development of antiviral compounds for other high-value indications.

Targeted Solutions for Viral Diseases

Novel antiviral therapeutics for the treatment of serious and/or chronic viral diseases including influenza, COVID-19, hepatitis C and gastroenteritis caused by norovirus.

View Product Pipeline

About Us

Cocrystal Pharma, Inc. is a clinical-stage biotechnology company discovering and developing novel antiviral therapeutics that target the replication process of influenza virus, SARS-CoV-2 virus, hepatitis C virus, and norovirus.

Learn More

Technology

We utilize unique structure-based technologies and Nobel Prize winning expertise to create first- and best-in-class antiviral drugs.

Learn More

Development Programs

Our development programs include a wide variety of serious and/or chronic viral diseases including influenza, COVID-19, hepatitis C and gastroenteritis caused by norovirus.

Learn More
Program Discovery Preclinical Phase 1 Phase 2a Phase 2b Phase 3
COVID-19 Oral Protease Inhibitor
Discovery Phase complete
Preclinical Phase in progress
Phase 1 Phase not started
Phase 2a Phase not started
Phase 2b Phase not started
Phase 3 Phase not started
COVID-19 (Licensed) CDI-45205 Protease Inhibitor
Discovery Phase complete
Preclinical Phase in progress
Phase 1 Phase not started
Phase 2a Phase not started
Phase 2b Phase not started
Phase 3 Phase not started
COVID-19 Replication Inhibitors
Discovery Phase in progress
Preclinical Phase not started
Phase 1 Phase not started
Phase 2a Phase not started
Phase 2b Phase not started
Phase 3 Phase not started
Influenza A CC-42344 PB2 Inhibitor
Discovery Phase complete
Preclinical Phase complete
Phase 1 Phase in progress
Phase 2a Phase not started
Phase 2b Phase not started
Phase 3 Phase not started
Influenza A/B

In collaboration with

Collaboration
Influenza A/B Inhibitor
Discovery Phase complete
Preclinical Phase complete
Phase 1 Phase complete
Phase 2a Phase complete
Phase 2b Phase complete
Phase 3 Phase complete
Hepatitis C (HCV) CC-31244 Pan-genotypic NS5B NNI
Discovery Phase complete
Preclinical Phase complete
Phase 1 Phase complete
Phase 2a Phase complete
Phase 2b Phase complete
Phase 3 Phase complete
Norovirus Gastroenteritis Replication and Protease Inhibitors
Discovery Phase complete
Preclinical Phase in progress
Phase 1 Phase not started
Phase 2a Phase not started
Phase 2b Phase not started
Phase 3 Phase not started

Investor Presentation

View our latest Corporate Presentation

View Presentation View Fact Sheet